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Abstract: Point‐of‐care viscoelastic coagulation tests are used increasingly and enable physicians to run
precise whole blood coagulation diagnostics. However, the somewhat complicated and abstract presen-
tation of results may hinder these advantages. For this reason, we developed the Visual Clot as an
alternative mode of presentation for thrombelastometric data. An algorithm takes existing parameters
from rotational thromboelastometry and creates a visual representation in the form of an animated blood
clot named ‘Visual Clot’. In a prospective international dual‐centre study, 60 physicians were presented
with rotational thromboelastometry results in the standard way or as a Visual Clot. They were then
asked to make therapeutic decisions based on pathological findings. Overall proportion of correct thera-
peutic decisions was median (IQR [range] 100 (83–100 [39–100]) % for Visual Clot vs. 44 (25–50 [0–83]) %
for standard rotational thromboelastometry presentation of results, p < 0.001. Mixed regression models
yielded a mean OR (95%CI) 22.1 (13.4–36.5), p < 0.001 for correct decisions with the Visual Clot com-
pared with standard rotational thromboelastometry, with an 18.7 (16.4–21.1), p < 0.001 second decrease
in decision time. Perceived cognitive work‐load was lower, and participants rated their diagnostic con-
fidence to be higher with the Visual Clot, both p < 0.001. Although correct interpretation of standard
rotational thromboelastometry results depended on previous rotational thromboelastometry knowledge
and experience, Visual Clot interpretation did not. The Visual Clot improved rotational thromboelas-
tometry‐based therapeutic decisions, as pathologies can be recognised more rapidly and accurately. These
findings underline the significance of an alternative additional visualisation technique that simplifies the
interpretation of abstract standard data.
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Point-of-care viscoelastic coagulation tests are used increasingly and enable physicians to run precise 
whole blood coagulation diagnostics. However, the somewhat complicated and abstract presentation 
of results may hinder these advantages. For this reason, we developed the Visual Clot as an 
alternative mode of presentation of thrombelastometric findings. An algorithm takes existing 
parameters from a ROTEM and creates a visual representation in the form of an animated blood clot 
named ‘Visual Clot’. In a prospective international dual-centre study, 60 physicians were presented 
ROTEM results in the standard way or as a Visual Clot. They were then asked to make therapeutic 
decisions based on pathological findings. Overall median percentage of correct therapeutic decisions 
was 100% (IQR 83-100 [range 39-100]) for Visual Clot compared to 44% (IQR 25-50 [range 0-83]) for 
standard ROTEM result, p<0.001. Mixed regression models yielded an odds ratio of 22.1 (95% CI 13.4 
to 36.5, p<0.001) for correct decision with the Visual Clot compared to the standard ROTEM, with an 
average 18.7 (95% CI 16.4 to 21.1, p<0.001) second decrease in decision time. Perceived cognitive 
workload was lower, and participants rated their diagnostic confidence to be higher with the Visual 
Clot, both p<0.001. While correct standard ROTEM result interpretation depended on previous 
ROTEM knowledge, Visual Clot interpretation did not. The Visual Clot improves ROTEM based 
therapeutic decisions, as pathologies can be recognized faster and more accurately. These findings 
underline the significance of an alternative, additional visualization technique, easing the 




Accurate diagnostic and individualized, goal-directed treatment are integral components of modern 
haemostatic management [1,2]. Its development has been facilitated by the implementation of 
point-of-care viscoelastic coagulation monitoring with rotational thromboelastometry (ROTEM) or 
thromboelastography (TEG). Global haemostasis assays like ROTEM and TEG allow rapid insights into 
complex coagulation systems and their possible dysfunction, fill the gap left by limitations of 
conventional laboratory tests. The use of viscoelastic testing is recommended in European guidelines 
for managing trauma and severe perioperative bleeding, as it helps to reduce transfusion of 
allogeneic blood products [1,3]. Its benefits have been shown not only in trauma induced 
coagulopathy [3,4], but also in obstetric haemorrhage [5,6], cardiac surgery [7,8], transplantation [9], 
burn surgery [10], and neurosurgery [11]. Further, viscoelastic tests play a role in the diagnosis and 
treatment adjustment of haematological disorders like haemophilia, multiple myeloma or inherited 
afibrinogenemia [12–15]. Although the use of viscoelastic testing is already widespread, its 
interpretation remains to some extent difficult. It requires well trained and supervised clinical 
personnel, to interpret the resulting tracings and raw parameters [16]. Its growing use in different 
fields by sometimes less experienced personnel calls for the development of an interpretation aid, 
substantially easing the first contact and read of a viscoelastic result. For this reason, we developed 
the Visual Clot as a simpler, situation awareness-based mode of presentation of viscoelastic results. 
An algorithm takes existing parameters from a standard ROTEM trace and in real time creates a 
visual representation in the form of an animated blood clot – hence the name ‘Visual Clot’. The Visual 
Clot was designed to enable a care provider to make the correct diagnosis as efficiently as possible, 
however, without making the diagnosis for the user. Thus, even with the Visual Clot, the human user 
remains the final decision maker and, thereby, remains in the loop of the decisions made. We 
hypothesize that the alternative visualization with the Visual Clot may improve ROTEM based 
decision-making regarding haemostatic management compared to the standard ROTEM result alone. 
We further hypothesize that the use of the Visual Clot leads to less perceived workload, and might 
improve diagnostic performance, and hence better therapeutic decisions.    
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Methods 
The two main principles of the Visual Clot are reduction of information complexity and direct display 
of goal-relevant information. The Visual Clot is made up of basic components of haemostasis: 
Platelets, plasmatic factors and fibrin are schematically presented in an animation, where each one 
can be either sufficient or deficient (Figure 1). If for example the ROTEM displays an adequate 
maximum clot firmness (MCF) in the FIBTEM channel, representing sufficient supply and 
polymerization of fibrin, the Visual Clot displays yellow strings of fibrin tying the clot together. 
However, if the FIBTEM’s MCF were too small, implying a fibrin deficiency, the yellow strings would 
disappear and be replaced by a placeholder in the form of a dashed line. We designed the Visual Clot 
according to principles of situation awareness, striving for better perception and comprehension of 
otherwise complicated data, which may lead to better decision making [17]. These design 
characteristics eliminate the need for care providers to calculate meaning from lower-level data (i.e., 
times, angles and amplitudes) of the raw standard ROTEM result traces. 
This study was an investigator-initiated, within-subject, prospective, dual-centre trial comparing two 
different methods to display ROTEM results. The leading ethics committee (cantonal ethic committee 
of Zurich, Switzerland) reviewed the study protocol and found that this study does not require their 
approval (Business Administration System for Ethics Committees Number 2018-00933), as the study 
does not include any data of real patients nor any human material whatsoever. 
We conducted the study with a total of 60 anaesthesiologists and intensivists in two large University 
hospitals experienced in ROTEM use: Half of the participants came from the University Hospital 
Zurich in Switzerland and the other half from the University Hospital Frankfurt in Germany. The 
selection of participants was random, as we randomly asked anaesthesiologists and intensivists 
during daily clinical practice in the operating room or intensive care unit to take part in the study – 
regardless of gender, age, degree, position or ROTEM knowledge.  
After signing a confidentiality agreement and completing a short demographic survey, participants 
were shown four introductory slides, explaining both the Visual Clot and the standard ROTEM result. 
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This short instruction of the Visual Clot and the standard ROTEM result took around five minutes. The 
participants were then shown 12 coagulation scenarios, one after another, in randomized sequences. 
These 12 scenarios represented 6 different haemostatic conditions, each of which was shown twice, 
once as a standard ROTEM result, and once as a matching Visual Clot. Randomization of the 
sequences was done by Research Randomizer Version 4.0 [http://www.randomizer.org/, retrieved 
on December 5, 2018]. The different scenarios with their correct solutions are available in 
Supplementary Video 1. For each scenario, we asked the following question: ‘If there are clinical 
signs of bleeding present, what treatment is required?’ with the following possible answers: 
‘Fibrinogen, platelets, tranexamic acid (antifibrinolytic), protamine (to reverse heparin effect), 
plasmatic factors, nothing (normal result or hypercoagulable).’ Multiple correct answers were 
possible. The scenarios were shown on an Acer Aspire V15 Nitro laptop (Acer Inc., New Taipei City, 
Taiwan) and the participants gave their answers on an iPad (Apple Inc., Cupertino, CA, U.S.A.) in 
iSurvey-based (Harvest Your Data, Wellington, New Zealand) data collection tool [18], which also 
measured the time to answer a question. After each of the 12 scenarios, participants self-rated their 
diagnostic confidence and their perceived workload. 
Each Visual Clot was created from a standard ROTEM, enabling direct comparisons of matched 
ROTEM result and Visual Clot pairs. The algorithm used to deduct Visual Clots from artificially created 
ROTEM data is available as Supplementary Table 1. 
The decision-making endpoint was assessed by having made a correct decision for each scenario. A 
decision was correct if all required and no incorrect treatments were selected. Depending on the 
scenario a single or multiple correct treatment were required. All other treatments were incorrect. 
Except in certain scenarios, where specific answers were not required, but also not incorrect (e.g. 
Tranexamic acid for fibrin deficiency). A detailed list of scenarios with correct, incorrect and optional 
answers is available in Supplementary Video 1. In each scenario the required treatments are marked 
green and optional treatments are marked yellow. 
 6 
Time-to-decision was measured in seconds. Diagnostic confidence was assessed after each scenario 
on a 4-point Likert scale (0 = very unconfident, 1 = unconfident, 2 = confident, 3 = very confident). 
Workload was also evaluated after each scenario by the National Aeronautics and Space 
Administration Task Load Index (NASA-TLX). The NASA-TLX consisted of only five questions, as the 
otherwise sixth question on ‘physical demand’ was removed for the purpose of this study. 
For descriptive statistics, we show medians with interquartile range (IQR) for continuous data and 
numbers and percentages for categorical data. Our outcome variables are the binary information 
about the treatment decision (correct/incorrect) and the time to decision, as well as the percentage 
of correct decisions for each participant and the confidence of each participant (scale from 0-3) and 
the perceived workload (NASA-TLX score). For an unadjusted comparison of ROTEM and Visual Clot, a 
nonparametric Wilcoxon test for paired data was used for the continuous outcome variables, and 
McNemar’s test was used for the binary outcome variable. Association of self-rated ROTEM 
knowledge and successful decision-making was assessed by Spearman’s correlation. For the 
comparison of ROTEM and Visual Clot with adjustment for potential confounders, mixed linear and 
generalized mixed linear models were used to additionally account for dependent measurements, 
i.e. measurements from the same participant: For the continuous variables, we calculated a linear 
mixed model with a random intercept per participant. For the binary outcome variable, we calculated 
a mixed logistic regression model with random intercept for each participant. Apart from the variable 
denoting the respective technology (ROTEM versus Visual Clot), all models were adjusted for the 
following confounders: centre, gender, experience (in years), the order in which the scenarios were 
looked at (e.g. being the first task, somewhere in the middle or the last one) and the respective 
scenario.  
Analyses were carried out in R Version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) 
and in GraphPad PRISM 8.1.1. (GraphPad Software Inc., CA, U.S.A.), where the figures were also 
created. A p-value of less than 0.05 was considered to indicate statistical significance.  
For original data, please contact David.Tscholl@usz.ch.   
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Results 
From Dec. 6. 2018 to Apr. 17. 2019, 60 anaesthesiologists and intensivists were recruited. All 60 
participants rated 12 scenarios, including 6 standard ROTEM result and 6 Visual Clot, in a randomized 
order, resulting in 360 direct comparisons. Of those, 11 paired scenarios were excluded after 
completion because of an error in a scenario discovered after data collection, leading to a total 
number of 349 pairs. 
The participants from the University Hospital Frankfurt were more experienced than the ones from 
the University Hospital Zurich, with a median experience of 9 years (IQR 6-12 [range 2-25]) compared 
to 5 years (IQR 2-10 [range 0-29]). Physicians from the University Hospital Frankfurt usually 
interpreted more ROTEM results in clinical routine (52 per year and physician, IQR 19-56 [range 2-
100]) than at the University Hospital Zurich (20 per year and physician, IQR 7-50 [range 0-100]) (Table 
1). 
Overall median percentage of correct therapeutic decisions was 44 % (IQR 25-50 [range 0-83]) for 
standard ROTEM result, compared to 100 % (IQR 83-100 [range 39-100]) for Visual Clot (Wilcoxon 
test; p < 0.001; Figure 2). Mixed logistic regression yielded an odds ratio (OR) of 22.1 (95% confidence 
interval (CI) 13.4 to 36.5, p < 0.001) for correct decision with the Visual Clot compared to the 
traditional ROTEM. This means that the odds of deciding correctly were 22.1 times higher if Visual 
Clot was used than for standard ROTEM. The complete mixed logistic regression model is shown in 
Supplementary Table 2.  
Participant-wise analysis showed that all but one participant was able to determine more correct 
answers regarding therapeutic decision-making with the Visual Clot than with the standard ROTEM 
result (Figure 3). Further, scenario-wise analysis showed that Visual Clot based decision-making was 
significantly superior to standard ROTEM result-based decision-making in 9 out of 11 scenarios. No 
difference in decision-making was found for the ‘Hyperfibrinolysis scenario’ and the ‘combined fibrin 
and plasmatic factor deficiency with hyperfibrinolysis’ (Table 2).  
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Median time to decision was 15 seconds (IQR 9-21 [range 4-84]) with Visual Clot, compared to 30 
seconds (IQR 18-47 [range 5-142]) with standard ROTEM result (p < 0.001) (Figure 2). Perceived 
workload was also significantly lower with Visual Clot than with standard ROTEM result, with median 
NASA-TLX scores of 31 (IQR 16-43 [range 0-76]) and 52 (IQR 38-65 [range 1-95]) respectively (p < 
0.001) (Figure 2). Participants rated their diagnostic confidence to be higher with the Visual Clot, 
(median “3 = very confident”, IQR “2 = confident” to “3 = very confident” [range “1 = unconfident” to 
“3 = very confident”]) than with the ROTEM (median “2 = confident”, IQR “1 = unconfident” to “3 = 
very confident” [range “0 = very unconfident” to “3 = very confident”]) (p < 0.001) (Figure 2). 
Accordingly, the generalized mixed linear model determined that using the Visual Clot leads to an on 
average 18.7 (95% CI 16.4 to 21.1, p < 0.001) second decrease in decision time, a reduction in 
workload by a mean of 20.1 (95 % CI 18.2 to 22.1, p < 0.001) points in the NASA-TLX and an increase 
in self-rated confidence by on average 0.8 points (95% CI 0.7 to 0.9, p < 0.001) on a four point Likert 
scale. The separate results for each study centre are shown in Supplementary Figures 1 and 2. 
A Spearman's rank correlation was calculated to assess the relationship between self-rated ROTEM 
knowledge and correct therapeutic decisions with both the standard ROTEM result and the Visual 
Clot. There was a statistically significant positive correlation between self-rated ROTEM knowledge 
and correct therapeutic decisions in the standard ROTEM result (rs = 0.259, p = 0.046). Correct 
therapeutic decisions based on the Visual Clot were independent from self-rated ROTEM knowledge 
(rs = -0.107, p = 0.42) (Figure 4). 
To validate the Visual Clot, we calculated the inter-rater reliability of all seven different animations 
used in the Visual Clot to represent different haemostatic conditions. The inter-rater-reliability of 




Analysing 349 within-subject comparisons of therapeutic decisions after Visual Clot and standard 
ROTEM based presentation of the results, we found that all but one participating physician was able 
to make more correct decisions with the Visual Clot - regardless of previous knowledge and 
experience with ROTEM technique. Overall, Visual Clot resulted in 100% correct therapeutic 
decisions while standard ROTEM resulted only in 44 %. This increase in correct decision-making was 
accompanied by faster decision times, and lower perceived workload. Participants were also more 
confident in their decision. We adjusted for possible confounders in a linear mixed model or a mixed 
logistic regression model, both using a random intercept for each participant to account for 
dependent observations. These models determined that by using the Visual Clot the odds of a correct 
therapeutic decision are increased by a factor of more than twenty, with the raters being about 18 
seconds faster in coming to a decision. 
To the best of our knowledge, this is the first study evaluating an alternative visualization technique 
for ROTEM trace results. However, avatar based representation of patient data has been shown to be 
beneficial in vital sign monitoring [19,20], as the perception of vital sign information was improved by 
presenting patient status as an animated patient avatar (i.e. improved recognition, greater 
confidence and lower workload) [19]. Both the patient avatar and Visual Clot technologies are 
reasonably similar, as both present medical data in the form of an animated avatar. One represents a 
patient and its vital sign, whereas the Visual Clot represents a blood clot and the preceding 
coagulation. Research into avatar based monitoring found it to enable quick situation recognition 
and to be generally regarded by users as intuitive, easy to learn as well as very helpful [21]. These 
qualities appear to be present in the Visual Clot as well, considering that all participants were first 
time users for Visual Clot and achieved high inter-rater-reliability. 
Objective, experience dependent and subjective, self-rated ROTEM knowledge dependent 
correlation analysis found positive associations between previous ROTEM experience and self-rated 
ROTEM knowledge and the ability to correctly interpret standard ROTEM results. However, no 
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correlation was found for the Visual Clot, where all participants regardless of ROTEM knowledge 
score and self-rated ROTEM knowledge showed similar results. While participants were used to 
interpret ROTEM as part of their clinical routine, no participant had seen the Visual Clot before taking 
part in this study. This supports the idea that avatar-based graphics are easy to understand and to 
learn, while the more complicated traditional ROTEM display requires more learning efforts and 
more practice. While more experienced ROTEM users also benefited from using the Visual Clot, 
beginners do benefit in particular. Accessibility to novel and unexperienced users is a known trait of 
avatar based monitoring [21].  
The superior performance of the Visual Clot design may be explained by its situation awareness 
based, user-centred design, facilitating neurophysiological visual processes. The goal of situation 
awareness-based design is to enable efficient human decision making, i.e., decisions that are 
accurate, quick, confident and require a low cognitive effort [17]. For example, in a situation with low 
thrombocytes, the thrombocytes in the Visual Clot are absent. In the conventional ROTEM traces, the 
decision-maker must first remember in which channels to look and what to look for (in this case, 
reduced maximum clot firmness in INTEM and EXTEM channels). According to logic, an easily 
understandable model preserves a logical commonality with the reality it mirrors [22]. For the Visual 
Clot, we designed a simplified blood clot containing simplified haemostasis components that may 
either be present or absent in a given situation. In the Visual Clot image, the level of abstraction of 
the raw ROTEM data is increased [23]. The need to compile a mental "picture", piece by piece, from 
low-level data is replaced by a look at an unambiguous image of the clotting situation. This image in 
avatar based monitoring is so clear, that it is even recognizable by peripheral vision alone [24]. 
Furthermore, the design of the Visual Clot provides a high degree of visual salience. The complexity 
of simultaneously identifying targets in one's visual field makes it a difficult neurophysiological task 
[25]. Thus, humans restrict complex object recognition to a small area or a few objects at any one 
time, with a focus on visually salient stimuli [26]. While visual salience is dependent on many factors, 
an animated object has higher salience than abstract tracings. These principles make the Visual Clot 
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and especially its patterns easily recognizable. Not surprisingly, hyperfibrinolysis was the only 
scenario in which decision-making was very good with both techniques the Visual Clot and standard 
ROTEM displays. Hyperfibrinolysis displayed by standard ROTEM is a unique fusiform object that can 
easily be diagnosed at a first glance. In this special condition, the Visual Clot had no additional 
advantage. 
While the benefits of improved decision making are clear, the reduced cognitive workload and 
greater diagnostic confidence are also relevant because both lessen psychological stress. Stress 
drains cognitive resources and may thus reduce information processing capacity [27,28]. This can 
impair decision-making and worsen performance [29,30]. 
In this study, we created an algorithm to generate a Visual Clot from a ROTEM from standard cut-off 
values, as well as clinical research into pathological thresholds for ROTEM. For this purpose, we 
chose the following ROTEM thresholds for the Visual Clot to register a pathology: INTEM-CT greater 
than 240 seconds, EXTEM-CT greater than 100 seconds, EXTEM-MCF less than 40 mm, and FIBTEM-
MCF less than 9 mm [31,32]. The algorithm accounts for multiple scenarios where certain thresholds 
may differ depending on other pathological values. As thresholds for haemostatic intervention are 
often specified in local standard operating procedures, consumers should be able to define their own 
thresholds for changes in Visual Clot in a market-ready product. 
In daily clinical practice the Visual Clot is not supposed to replace standard ROTEM results but is 
meant to complement it in a way, where each health care professional can adapt the use of the 
Visual Clot individually to their needs.  
Our study had some limitations. The interpretation of ROTEM and Visual Clot took place in a testing 
environment by using simulated data. Therefore, it may be possible that the results of our study have 
exaggerated a potential real-world effect. However, ROTEM traces from daily clinical work, are often 
less pronounced and would be more difficult to assess correctly. To avoid any ambiguity, we opted to 
use artificially created ROTEMs. This represents an ideal situation for traditional ROTEM traces and 
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thus our study might also underestimate the true difference between traditional ROTEM traces and 
Visual Clot. Given the strength and consistency of the results, an adequate translation into real world 
effects is highly probable. Further, the scenarios were independent of clinical cases. Participants had 
the information that the ROTEM and Visual Clot fit the associated clinical picture, but in clinical 
practice interpretation of ROTEM is always case dependent. In the future, simulator-based studies 
may show if therapeutic benefit exists in a more clinical environment by expanding simulation and 
embedding the Visual Clot into clinical scenarios. On the other hand, this simulation method 
guaranteed that there was no influence on the interpretation of the findings by other, clinical factors. 
The design enabled us to show the sole effect of our novel technology in this first ever study on the 
Visual Clot. 
The study also had particular strengths. The international, dual-centre design makes the local effects 
unlikely. The within-subject design increases internal validity and the sample size adequately 
powered the analyses. 
The 3D Visual Clot improves therapeutic decisions based on viscoelastic testing, as pathologies can 
be recognized more accurately, faster, with greater confidence and reduced perceived workload. 
These findings warrant further clinical testing of this simple, situation awareness-based visualization, 
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Table 1 Study and participant characteristics. Values are medians (IQR [range]) or number 
(proportion). 
Number of participants 60 
Number of different ROTEM cases rated 11 
Number of direct comparisons between ROTEM and Visual Clot 349 
 Zurich Frankfurt 
Number of participants at study site 30 30 
Sex; female (%) 14 (47) 9 (30) 
Participants position 
Senior physician (%) 







Anaesthesia experience of physicians; years 5 (2-10 [0-29]) 9 (6–12 [2-25]) 
ROTEMS interpreted by physicians per year; number 20 (7-50 [0-100]) 52 (19-56 [2-100]) 
Duration per data collection; minutes 22 (20-26 [11-45]) 20 (17-22 [12-34]) 
 21 
Table 2: Scenario based results for both study centres. Values are medians (IQR [range]) or number 
(proportion). Perceived diagnostic confidence: 0=very unconfident, 1=unconfident, 2=confident, 
3=very confident. Perceived workload: NASA=National Aeronautics and Space Association, TLX= Task 
Load Index. 
Case ROTEM Visual Clot P-value 
1. Normal (10min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
17/24 (71) 
49 (27-65 [16-109]) 
2 (1-2 [0-3]) 
58 (39-69 [0-90]) 
 
24/24 (100) 
12 (7-19 [4-27]) 
3 (3-3 [2-3]) 






2. Normal (60min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
21/36 (58) 
18 (11-37 [7-103]) 
2 (1-3 [0-3]) 
45 (28-55 [0-75]) 
 
34/36 (95) 
8 (6-12 [4-36]) 
3 (2-3 [1-3]) 






3. Fibrin deficiency (10min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
5/24 (21) 
49 (38-56 [12-116]) 
1 (1-2 [0-3]) 
55 (46-67 [20-85]) 
 
22/24 (92) 
19 (15-34 [9-57]) 
2 (2-3 [1-3]) 






4. Platelet deficiency (10min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
8/36 (22) 
34 (22-46 [9-103]) 
1 (1-2 [0-3]) 
50 (41-65 [20-95]) 
 
32/36 (89) 
13 (8-18 [6-23]) 
3 (2-3 [1-3]) 






5. Plasmatic coagulation factor deficiency (60min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
10/36 (28) 
27 (15-38 [5-85]) 
2 (1-2 [0-3]) 
50 (35-65 [15-80]) 
 
31/36 (86) 
20 (15-26 [5-47]) 
2 (2-3 [1-3]) 






6. Hyperfibrinolysis (60min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
13/18 (72) 
35 (22-44 [10-64]) 
2 (1-2 [1-3]) 
56 (45-65 [14-75]) 
 
16/18 (89) 
13 (11-16 [6-48]) 
2 (2-3 [1-3]) 






7. Heparin effect (60 min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
10/24 (42) 
45 (29-68 [8-135]) 
2 (1-2 [0-3]) 
53 (40-65 [15-75]) 
 
22/24 (92) 
16 (13-26 [8-42]) 
3 (2-3 [1-3]) 






8. Hypercoagulability (10 min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
28/36 (78) 
16 (9-36 [5-139]) 
2 (1-3 [0-3]) 
43 (15-55 [0-75]) 
 
36/36 (100) 
10 (6-16 [4-38]) 
3 (2-3 [1-3]) 






9. Platelet deficiency masked by high fibrin (60 min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
2/60 (3) 
25 (13-37 [6-142]) 
2 (1-3 [0-3]) 
50 (39-60 [0-90]) 
 
57/60 (95) 
15 (10-22 [5-84]) 
3 (2-3 [1-3]) 







10. Fibrin, platelet and plasmatic factor deficiency (60min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  
• Perceived workload NASA TLX score 
 
9/19 (47) 
30 (24-43 [12-75]) 
2 (1-2 [1-3]) 
60 (40-65 [30-83]) 
 
17/19 (89) 
23 (19-34 [9-79]) 
2 (2-3 [1-3]) 






11. Fibrin and plasmatic factor deficiency with 
hyperfibrinolysis (60min) 
• Correct decisions 
• Time to decision in seconds 
• Perceived diagnostic confidence  




28 (19-43 [10-102]) 
2 (1-2 [0-3]) 




21 (16-30 [10-80]) 
2 (2-3 [1-3]) 











Figure 1: The Visual Clot. (A) This scanning electron micrograph of a blood clot depicts red blood cells 
and platelets enmeshed in a fibrinous matrix. The Visual Clot was modelled after this image. This 
image has been released into the public domain by its author Janice Haney Carr (retrieved from the 
Centers for Disease Control and Prevention’s Public Health Image Library on May 17th 2019; Image ID: 
7308). (B) The different animations representing basic haemostatic components. (C) A normal Visual 
Clot, with no pathologies. (D) The Visual Clot with fibrin, factor, platelet deficiency and 
hyperfibrinolysis. A HEPTEM was run, but no heparin effect was found. The bleeding effect occurs, if 
anything is abnormal.  
 
Figure 2: Example scenario of a ROTEM with a corresponding Visual Clot. The scenario displays a 
plasmatic factor deficiency, as shown by the prolonged clotting time (CT) in the (A) ROTEM EXTEM 
and INTEM channel or the missing plasmatic factors in the (B) Visual Clot. This scenario would be 





Figure 3: Overall group differences between the standard ROTEM display and the Visual Clot. Box 
plots are medians with interquartile range, whiskers are 5-95 percentile, dots are individual outliers. 
Perceived diagnostic confidence: 0=very unconfident, 1=unconfident, 2=confident, 3=very confident. 
Perceived workload: NASA=National Aeronautics and Space Administration, TLX= Task Load Index. N 





Figure 4: Decision-making on an individual participant level. Percentage of correct answers for each 
of the 60 participants ranked on the X-axis from left to right according to achieved percentage of 




Figure 5: Spearman’s correlation of self-rated ROTEM knowledge and correct decisions for each 
participant.  
 
 
 
